Company: TXG
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001770787-25-000018
Chunk: 26

Company: 10x Genomics, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 26
---
     |             |     |  71,407 |     |        |     | 186,645 |     | 258,052 |
| Shehnaaz Suliman     |     |             |     |  65,110 |     |        |     | 186,645 |     | 251,755 |
| Sarah Teichmann(5)   |     |             |     |  26,155 |     |        |     | 443,697 |     | 469,852 |

(1) The fees paid to non-employee directors are described above under the heading “Non-Employee Director Compensation Policy.”

(2) The amounts shown represent the grant date fair value of the equity awards granted to our non-employee directors in fiscal year 2024, as computed in accordance with FASB ASC Topic 718 and is based upon the market price of our Class A common stock on the date of grant. There can be no assurance that the restricted stock units ("RSUs") will vest in full (in which case no value with respect to such RSUs will be realized by the individual) or that the value upon exercise or upon vesting, as applicable, will approximate the fair value as computed in accordance with FASB ASC Topic 718. As of December 31, 2024, the aggregate number of outstanding stock options to purchase shares of our Class A common stock held by each of our non-employee directors who served during fiscal year 2024 included: Mr. Kosaraju, 100,123; Ms. Popovits, 26,286; Dr. Stuelpnagel, 15,956; and Dr. Suliman, 115,956. Drs. Mammen and Teichmann and Mr. Mateo held no outstanding options as of December 31, 2024. As of December 31, 2024 the aggregate number of outstanding RSUs which vest and settle into shares of our Class A common stock held by each of our non-employee directors who served during fiscal year 2024 included: Mr. Kosaraju, 4,325; Dr. Mammen, 7,500; Mr. Mateo, 21,691; Ms. Popovits, 4,325; Dr. Stuelpnagel, 4,325; Dr. Suliman, 4,325; and Dr. Teichmann, 19,002.

#### 10